How a Global Network Accelerated the Development of a Virus-Like Particle Vaccine Against Covid-19

by Ute Boronowsky | February 28, 2022


How a Global Network Accelerated the Development of a Virus-Like Particle Vaccine Against Covid-19

Setting up the logistics and cold chain infrastructure needed for vaccine deployment is expensive and cumbersome, contributing to low vaccination rates in African countries. Enabling local vaccine manufacturing in sufficient quantities and consistent quality could have a significant impact in fighting infectious diseases, including the Covid-19 pandemic.

A partnership between the biotech companies TechnoVax in the US, MilliporeSigma*, and Innovative Biotech in Nigeria aims to empower vaccine development in Africa. Innovative Biotech has developed vaccines against Ebola and HIV, and with the onset of the Covid-19 pandemic, the company quickly switched to the new target.

Learn More about this online article HERE. 

Register now for the free on-demand webinar HERE. 

* MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany

[starbox id=”UteBoronowsky”]


Related Posts

Hiring Challenges in Bioprocessing for Start-ups

Creating Bottlenecks in Europe; Opportunities for Production Staff BioPlan Associates, Inc. Hiring of bioprocessing professionals has remained a…

When to sprint and when to breathe in the race from lab to clinic – 5 critical steps to success

As an early-stage or small-sized biotech company, you need to move fast and be nimble.  Success is measured…

Starting your journey into manufacturing – choosing a cell line development provider

One of the biggest decisions which any company developing biological medicines makes is to move forward to the manufacture of their product. …

A Streamlined Approach to Analytical Method Development and Implementation

The development and implementation of analytical methods are essential for success at all phases of a molecule’s journey,…

Scroll to Top